PB 007

Drug Profile

PB 007

Latest Information Update: 05 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflabloc Pharmaceuticals
  • Class Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Cell differentiation stimulants; DNA-directed RNA polymerase stimulants; Immunosuppressants; Intercellular signalling peptide and protein stimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders; Reperfusion injury

Most Recent Events

  • 05 Dec 2003 No development reported - Preclinical for Neurological disorders in USA (Injection)
  • 05 Dec 2003 No development reported - Preclinical for Reperfusion injury in USA (Injection)
  • 25 Jan 2000 Preclinical development for Neurological disorders in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top